



NDA 203137/S-013

SUPPLEMENT APPROVAL

GE Healthcare Inc.
Attention: Alletah Schmidt
Regulatory Affairs & Labeling Project Manager
100 Results Way
Marlborough, MA 01752

Dear Alletah Schmidt:

Please refer to your supplemental new drug application (sNDA) dated and received September 11, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vizamyl™ (Flutemetamol F18 Injection).

We also refer to our letter dated June 17, 2019 of Prior Approval Supplement Request – PLLR Format notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for Vizamyl. These Prior Approval supplemental new drug applications provide labeling according to Physician Labeling Rule (PLR)/Pregnancy and Lactation Labeling Rule (PLLR) format per the content and format regulations found at 21 CFR 201.56(a and d) and 201.57 (c)(9)(i, ii, and iii).

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lisa Skarupa, Regulatory Project Manager, at 301-796-2219.

Sincerely,

{See appended electronic signature page}

Libero Marzella, M.D., Ph.D.
Director
Division of Medical Imaging Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LIBERO L MARZELLA
01/10/2020 01:16:21 PM